Skip to main content
Equibles

Stacy Lindborg

CEO

Imunon, Inc. (IMNN)

Board Member

Imunon, Inc. (IMNN)

Equibles does not estimate personal net worth.

Get an email with a short summary when Imunon, Inc. publishes a filing, an earnings call transcript or a press release.

Get IMNN alerts

About Stacy Lindborg

Stacy Lindborg is recorded as CEO and Board Member at Imunon, Inc. (IMNN). The proxy statement of Imunon, Inc. reports total compensation of $1,029,349 for Stacy Lindborg in fiscal 2025, including a base salary of $568,139. Disclosed compensation is on record for 2 fiscal years. Stacy Lindborg has spoken on 7 earnings calls across 1 company, most recently for Imunon, Inc. on November 13, 2025. Imunon, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Imunon, Inc. includes Corinne Le Goff (CEO and Board Member), Michael Tardugno (CEO and Chairman), Stacy R. Lindborg (CEO and Board Member) and 7 others.

Stacy Lindborg on recent calls

“Joining me on the call this morning is Dr. Douglas Faller, our Chief Medical Officer, and Ms. Kim Graper, our Interim Chief Financial Officer, who will be reviewing our financial results for the third quarter of 2025.”
CEO, Imunon, Inc. Q3 FY2025 Earnings Call ·
“Joining me on the call this morning is Dr. Douglas Faller, IMUNON's Chief Medical Officer; and Ms. Kimberly Graper, our Interim Chief Financial Officer, who will review our financial results for the second quarter 2025.”
CEO, Imunon, Inc. Q2 FY2025 Earnings Call ·
“Joining me on this call is Dr. Douglas Faller, Imunon's Chief Medical Officer; and David Gaiero, our Interim Chief Financial Officer who will review our financial results for the first quarter of 2025.”
CEO, Imunon, Inc. Q1 FY2025 Earnings Call ·
“Joining me on this call is Dr. Douglas Fowler, Imunon, Inc.'s new Chief Medical Officer who joined earlier this month, and Dave Gaiero, our interim Chief Financial Officer who will review our financial results for 2024.”
CEO, Imunon, Inc. Q4 FY2024 Earnings Call ·
“I'd like to begin by noting that Michael Tardugno, the Executive Chairman of our Board; and Khursheed Anwer, our Chief Scientific Officer are both on the line and will be available for Q&A. David Gaiero, our Interim Chief Financial Officer will review our financial results following my remarks.”
CEO, Imunon, Inc. Q3 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at Imunon, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Imunon, Inc. (IMNN) $568,139 $1,029,349
2024 Imunon, Inc. (IMNN) $341,954 $1,189,339

Recent activity